Aptorum Group Limited (APM)

Market Cap	6.80M +11.3%
Revenue (ttm)	n/a
Net Income	-1.36M
EPS	-0.19
Shares Out	8.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,915
Open	0.8350
Previous Close	0.8109
Day's Range	0.8200 - 0.8499
52-Week Range	0.6500 - 4.4700
Beta	0.09
Analysts	Strong Buy
Price Target	150.00 (+17,874.84%)
Earnings Date	Mar 31, 2026

About APM

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pse...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 18, 2018
• Employees: 1
• Stock Exchange: NASDAQ
• Ticker Symbol: APM
• Website: https://www.aptorumgroup.com

Analyst Summary

According to one analyst, the rating for APM stock is "Strong Buy" and the 12-month stock price target is $150.0.

Price Target

$150.0

(17,874.84% upside)

Analyst Consensus: Strong Buy